Results 11 to 20 of about 25,701 (209)

Estudio de las variantes alélicas CYP2C9*2 y CYP2C9*3 en muestras de población mestiza peruana [PDF]

Biomédica: revista del Instituto Nacional de Salud, 2019
Introducción. El citocromo CYP2C9 metaboliza, aproximadamente, el 15 % de los fármacos prescritos. Su gen presenta alelos cuyas frecuencias difieren entre grupos étnicos y poblaciones. Los alelos CYP2C9*2 y CYP2C9*3 dan cuenta de una enzima con actividad
Ángel Tito Alvarado, Ana María Muñoz, Berta Loja, Jessica Michiko Miyasato, Jorge Antonio García, Roberto Andrés Cerro, Luis Abel Quiñones, Nelson Miguel Varela   +7 more
doaj   +2 more sources

Phenotypical and functional characterization of a HepG2 cell clone stably overexpressing cytochrome P450 (CYP) 2C9 [PDF]

BMC Research Notes
Objective We aimed to generate a HepG2 cell clone stably overexpressing cytochrome P450 (CYP) 2C9 together with an empty vector (EV) control cell clone for pharmacological and toxicological studies of substances with CYP2C9-mediated biotransformation ...
Sarah Kammerer, Natalie Herzog, Thea Jenchen, Valentina Stock, Rebecca Hofer, Veronika Ruzsanyi, Jan-Heiner Küpper   +6 more
doaj   +2 more sources

Pharmacogenetics: Influence of CYP2C9*2 and *3 alleles polymorphisms on Iraqi type 2 diabetic patients

Medical Journal of Babylon
Background: Sulfonylureas (SUs) are the most prescribed anti-diabetic drugs. The enzyme responsible for metabolizing of SUs is hepatic cytochrome P4502C9 (CYP2C9).
Ghada S. Rasool, Asmaa A. Hussien, Suhad R. Al-Tayie, Salwa J. Al-Awadi, Hussein OM Al-Dahmoshi   +4 more
doaj   +2 more sources

CYP2C9*2 and CYP2C9*3 allele variants of CYP2C9 cytochrome gene in St. Petersburg population, and their clinical role in warfarin anticoagulant therapy

Российский кардиологический журнал, 2004
One of the leading anticoagulants in Russia is warfarin. Its pharmacokinetics is determined by structural polymorphisms of CYP2C9 cytochrome gene, metabolizing warfarin.
O. V. Sirotkina, A. S. Ulitina, A. E. Taraskina, M. I. Kadinskaya, T. V. Vavilova, S. N. Pchelina, E. I. Shwartz   +6 more
doaj   +1 more source

Functional Characterisation of Human CYP2C9 Allelic Variants in COS-7 cells [PDF]

Frontiers in Pharmacology, 2016
Variability in activity of CYP2C9, which is involved in the metabolism of approximately 15% of current therapeutic drugs, is an important contributor to interindividual differences in drug response.
Huihui eDu, Zhiyun eWei, Yucai eYan, Yuyu eXiong, Xiaoqing eZhang, Lu eShen, Yunfeng eRuan, Xi eWu, Qingqing eXu, Lin eHe, Shengying eQin   +10 more
doaj   +2 more sources

Mathematical modeling of pharmacokinetics and pharmacodynamics of losartan in relation to CYP2C9 allele variants [PDF]

Frontiers in Systems Biology
Losartan is a selective angiotensin II AT1-receptor antagonist for the treatment of arterial hypertension and heart failure. It is converted to a pharmacologically active metabolite carboxylosartan (E-3174) in the liver mainly by CYP2C9 enzyme, a member ...
Dmitry Babaev, Elena Kutumova, Elena Kutumova, Fedor Kolpakov, Fedor Kolpakov   +4 more
doaj   +2 more sources

Cytochrome P450-Catalyzed Hydroxylation of Δ8-Tetrahydrocannabinol and Implications for Pharmacogenetics [PDF]

Pharmaceutics
Introduction: The use of Δ8-tetrahydrocannabinol (Δ8-THC) has become increasingly prevalent in the United States, but its metabolic pathways remain poorly characterized.
Mengqi Zhao, Philip Lazarus
doaj   +2 more sources

The Effect of Dicloxacillin Administration on Pharmacokinetics of Narrow Therapeutic Window Drugs: Phenytoin and Warfarin. [PDF]

Clin Pharmacol Ther
Dicloxacillin is a penicillinase‐resistant beta‐lactam antibiotic and potent activator of the Pregnane X receptor (PXR), known to induce CYP2C9, CYP2C19, and CYP3A4 activity. Clinical data suggest it reduces anticoagulation in warfarin‐treated patients and increases the risk of thromboembolic events.
Shaul C, Mujahed W, Idries I, Wanounou M, Bialer M, Caraco Y.   +5 more
europepmc   +2 more sources

Impact of genetic and non-genetic factors on hepatic CYP2C9 expression and activity in Hungarian subjects

Scientific Reports, 2021
CYP2C9, one of the most abundant hepatic cytochrome P450 enzymes, is involved in metabolism of 15–20% of clinically important drugs (warfarin, sulfonylureas, phenytoin, non-steroid anti-inflammatory drugs).
Ferenc Fekete, Katalin Mangó, Máté Déri, Evelyn Incze, Annamária Minus, Katalin Monostory   +5 more
doaj   +1 more source

Clinical significance of the series of CYP2C9*non3 variants, an unignorable predictor of warfarin sensitivity in Chinese population

Frontiers in Cardiovascular Medicine, 2022
BackgroundsGene polymorphisms are critical for variations in warfarin dose. To date, more than 70 CYP2C9 alleles have been identified. This study was designed to clarify the clinical significance of CYP2C9*non-3 variants to warfarin sensitivity in ...
Dongxu Wang, Dongxu Wang, Hualan Wu, Min Dong, Qing Zhang, Anxu Zhao, Xinlong Zhao, Jia Chong, Minghui Du, Yan Wang, Haifeng Shi, Shuanghu Wang, Fang Wang, Jianping Cai, Jiefu Yang, Dapeng Dai, Hao Chen   +16 more
doaj   +1 more source